Phaarmasia Ltd.
BSE: PHRMASI · Pharmaceuticals · sector
₹83.10BSE close 2026-10-26
Key numbers
Market cap₹57 cr
Price₹83.10
52w high / low₹132 / ₹30
P/E3.0xSector median 27.9x
P/B2.6xSector median 2.9x
Book value₹32.4
Dividend yield–Sector median 0.48%
ROE114.5%Sector median 11.7%
ROCE93.0%Sector median 12.3%
OPM42.8%Sector median 14.0%
Debt / equity0.05xSector median 0.16x
EV/EBITDA2.2xSector median 18.6x
Interest cover105.6x
Current ratio3.46x
Sales growth 3y+19.8%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.02x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹11 cr vs borrowings ₹1 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 105.6x in the last 12 months.
- Net loss in 2 of the last 6 quarters.
- Other income was 5% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹83.10 on 2026-10-26: -36.9% from the 52-week high, +174.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹124.25 · low ₹25.56
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 5 | 7 | 17 | 16 | 8 | 8 |
| EBITDA | -1 | 0 | 2 | 20 | -1 | 0 |
| OPM % | -11.4% | 1.3% | 9.7% | 123.6% | -8.7% | 0.6% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -1 | 0 | 2 | 16 | -1 | 0 |
| EPS (₹) | 0.77 | 0.40 | 2.54 | 23.84 | 1.03 | 0.50 |
| Revenue YoY | +42.4% | +20.5% | ||||
| Profit YoY | – | +25.9% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 17 | 27 | 31 | 24 | 47 | 49 |
| EBITDA | -2 | -2 | -1 | -2 | 21 | 21 |
| Net profit | -2 | -1 | -1 | -2 | 18 | 18 |
| EPS (₹) | -2.27 | 1.84 | -0.76 | 2.33 | 25.74 | 27.91 |
| Revenue growth | +59.6% | +11.3% | -20.3% | +93.7% | – | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +19.8% | – | – |
| Net profit | – | – | – |
| EPS | +141.0% | – | – |
| Share price | – | +29.8% (2y) | +144.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 9 | 22 |
| Borrowings | 0 | 1 |
| Cash & equivalents | 0 | 11 |
| Total assets | 22 | 30 |
| Fixed assets | 12 | 1 |
| Capital work in progress | – | 0 |
| Investments | 0 | 0 |
| Receivables | 3 | 5 |
| Inventory | 3 | 4 |
| Payables | 12 | 2 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 0 | -16 |
| Cash from investing | -0 | 26 |
| Cash from financing | -0 | 1 |
| Capex | 0 | 0 |
| Free cash flow | -0 | -16 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -18.2% | 79.5% |
| ROCE % | -18.2% | 93.1% |
| Debtor days | 47 | 40 |
| Inventory days | 57 | 48 |
| Payable days | 224 | 23 |
| Cash conversion cycle (days) | -120 | 65 |
| Working capital days | -66 | 147 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| PHRMASI | ₹57 cr | 3.0x | 2.6x | 114.5% | 93.0% | 42.8% | +19.8% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | PHRMASI |
| BSE code | 523620 |
| ISIN | INE486I01016 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.